Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.49 |
| ▸ | CHRM2 | P08172 | 4/20 | 0.41 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.41 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL951881 | 1.00 | NR1H4 (0.49) | NR1H4CHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL15934142 | 1.00 | NR1H4 (0.49) | NR1H4CHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL12332018 | 0.95 | NR1H4 (0.50) | NR1H4CHRM2CHRM4CHRM5CHRM1 | |
| Hydrochloric Acid SCHEMBL19746025 | 0.93 | NR1H4 (0.49) | NR1H4CHRM2CHRM4CHRM5CHRM1 | |
| Hydrochloric Acid SCHEMBL19746266 | 0.93 | NR1H4 (0.49) | NR1H4CHRM2CHRM4CHRM5CHRM1 | |
| Hydrochloric Acid SCHEMBL19746268 | 0.93 | NR1H4 (0.49) | NR1H4CHRM2CHRM4CHRM5CHRM1 | |
| Hydrochloric Acid SCHEMBL16400391 | 0.93 | NR1H4 (0.49) | NR1H4CHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL17464833 | 0.87 | CHRM2 (0.44) | NR1H4CHRM2 | |
| SCHEMBL15934209 | 0.87 | CHRM2 (0.44) | NR1H4CHRM2 | |
| Trifluoroacetic Acid SCHEMBL953944 | 0.86 | NR1H4 (0.40) | NR1H4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190084981-A1 | Bromodomain Inhibitors | ABBVIE INC (US) | 2019-03-21 | — | — | US | disclosed |
| US-10131657-B2 | Bromodomain inhibitors | ABBVIE INC. (US) | 2018-11-20 | — | — | US | disclosed |
| US-9957263-B2 | Bromodomain inhibitors | ABBVIE INC. (US) | 2018-05-01 | — | — | US | disclosed |
| EP-3008055-B1 | TETRAZOLONE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2017-07-19 | — | — | EP | disclosed |
| US-20160272630-A1 | Bromodomain Inhibitors | ABBVIE INC. (US) | 2016-09-22 | — | — | US | disclosed |
| US-20160185769-A1 | Bromodomain Inhibitors | ABBVIE INC. (US) | 2016-06-30 | — | — | US | disclosed |
| EP-3013827-A1 | BROMODOMAIN INHIBITORS | AbbVie Inc. (US) | 2016-05-04 | — | — | EP | disclosed |
| EP-3013828-A1 | BROMODOMAIN INHIBITORS | AbbVie Inc. (US) | 2016-05-04 | — | — | EP | disclosed |
| CN-105531273-A | Bromodomain inhibitors | ABBVIE INC | 2016-04-27 | — | — | CN | disclosed |
| CN-105518007-A | BROMODOMAIN INHIBITORS | ABBVIE INC | 2016-04-20 | — | — | CN | disclosed |
| EP-2238128-B1 | HETEROCYCLIC PYRAZOLE-CARBOXAMIDES AS P2Y12 ANTAGONISTS | SANOFI SA (FR) | 2012-08-22 | — | — | EP | disclosed |
| WO-2012054510-A1 | OXADIAZOLE COMPOUNDS WHICH INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF | COMENTIS, INC. (US) | 2012-04-26 | — | — | WO | disclosed |
| WO-2012028563-A1 | BACE INHIBITORS FOR USE IN THE TREATMENT OF DIABETES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-03-08 | — | — | WO | disclosed |
| US-20120053200-A1 | BACE 2 INHIBITORS | HOFFMANN-LA ROCHE INC. | 2012-03-01 | — | — | US | disclosed |
| US-20110021537-A1 | HETEROCYCLIC PYRAZOLE-CARBOXAMIDESAS P2Y12 ANTAGONISTS | SANOFI-AVENTIS (FR) | 2011-01-27 | — | — | US | disclosed |
| EP-2238128-A2 | HETEROCYCLIC PYRAZOLE-CARBOXAMIDES AS P2Y12 ANTAGONISTS | Sanofi-Aventis (FR) | 2010-10-13 | — | — | EP | disclosed |
| US-20100135999-A1 | QUINOLINE-CARBOXAMIDE DERIVATIVES AS P2Y12 ANTAGONISTS | SANOFI-AVENTIS (FR) | 2010-06-03 | — | — | US | disclosed |
| EP-2148871-A1 | QUINOLINE-CARBOXAMIDE DERIVATIVES AS P2Y12 ANTAGONISTS | Sanofi-Aventis (FR) | 2010-02-03 | — | — | EP | disclosed |
| WO-2009080226-A2 | HETEROCYCLIC PYRAZOLE-CARBOXAMIDES AS P2Y12 ANTAGONISTS | SANOFIS-AVENTIS (FR) | 2009-07-02 | — | — | WO | disclosed |
| WO-2008128647-A1 | QUINOLINE-CARBOXAMIDE DERIVATIVES AS P2Y12 ANTAGONISTS | SANOFI-AVENTIS (FR) | 2008-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100135999-A1 | QUINOLINE-CARBOXAMIDE DERIVATIVES AS P2Y12 ANTAGONISTS | P2RY12, P2RY1, P2RY2 | NR1H4 1961/4885CHRM2 38/4885CHRM4 109/4885 |
| US-20190084981-A1 | Bromodomain Inhibitors | BRD4, BRD1, BRD3 | NR1H4 1502/4885CHRM2 295/4885CHRM4 585/4885 |
| US-20110021537-A1 | HETEROCYCLIC PYRAZOLE-CARBOXAMIDESAS P2Y12 ANTAGONISTS | P2RY1, P2RY12, P2RY11 | NR1H4 2095/4885CHRM2 161/4885CHRM4 596/4885 |
| US-10131657-B2 | Bromodomain inhibitors | BRD1, BRD4, BRD3 | NR1H4 1415/4885CHRM2 272/4885CHRM4 556/4885 |
| US-20160272630-A1 | Bromodomain Inhibitors | BRD4, BRDT, EP300 | NR1H4 819/4885CHRM2 3610/4885CHRM4 4044/4885 |
| US-20120053200-A1 | BACE 2 INHIBITORS | BACE2, BACE1, PSEN2 | NR1H4 1342/4885CHRM2 3953/4885CHRM4 4698/4885 |
| US-20160185769-A1 | Bromodomain Inhibitors | BRD1, BRD4, BRD3 | NR1H4 1415/4885CHRM2 272/4885CHRM4 556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.